BartalenaL, KahalyGJ, BaldeschiL, et al.The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol, 2021; 185(4):G43–G67.
3.
LindholmJ, LaurbergP.Hyperthyroidism, exophthalmos, and goiter: Historical notes on the orbitopathy. Thyroid, 2010; 20(3):291–300.
GravesR.Newly observed affection of the thyroid. London Med Surg Jo, 1835; 7:513–520.
6.
DaviesTF, BurchHB. UpToDate. Wolters Kluwer: Alphen aan den Rijn, The Netherlands; 2022: v. 19.
7.
BartalenaL, BaldeschiL, DickinsonA, et al.Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol, 2008; 158(3):273–285.
TramontanoD, CushingGW, MosesAC, et al.Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. Endocrinology, 1986; 119(2):940–942.
10.
BahnRS.TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest, 2004; 27(3):216–220.
11.
KriegerCC, NeumannS, PlaceRF, et al.Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins. J Clin Endocrinol Metab, 2015; 100(3):1071–1077.
12.
SmithTJ, KahalyGJ, EzraDG, et al.Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med, 2017; 376(18):1748–1761.
13.
FurmaniakJ, SandersJ, SandersP, et al.TSH receptor specific monoclonal autoantibody K1-70(TM) targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial. Clin Endocrinol (Oxf), 2022; 96(6):878–887.
